A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg (DWCZP-I-1)

This study has been completed.
Sponsor:
Collaborators:
The Catholic University of Korea
Konkuk University Hospital
Naju National Hospital
Seoul National Hospital
Wonkwang University
DongGuk University
Information provided by (Responsible Party):
Dong Wha Pharmaceutical Co. Ltd.
ClinicalTrials.gov Identifier:
NCT01654601
First received: July 25, 2012
Last updated: February 13, 2014
Last verified: February 2014

July 25, 2012
February 13, 2014
June 2012
April 2013   (final data collection date for primary outcome measure)
Maximum Concentration of Clozapine in Plasma [ Time Frame: Up to 12hours ] [ Designated as safety issue: Yes ]
  • Cmax,ss of Clozapine in plasma [ Time Frame: Up to 12hr ] [ Designated as safety issue: Yes ]
    Pharmacokinetics
  • AUC0-12h,ss of Clozapine in plasma [ Time Frame: Up to 12hr ] [ Designated as safety issue: Yes ]
    Pharmacokinetics
Complete list of historical versions of study NCT01654601 on ClinicalTrials.gov Archive Site
  • Time to Reach Maximum Concentration of Clozapine in Plasma [ Time Frame: Up to 12hours ] [ Designated as safety issue: Yes ]
  • Terminal Half Life of Clozapine in Plasma [ Time Frame: Up to 12hours ] [ Designated as safety issue: Yes ]
  • Accumulation Rate of Clozapine in Plasma [ Time Frame: Up tp 12hours ] [ Designated as safety issue: Yes ]
  • Tmax of Clozapine in plasma [ Time Frame: Up to 12hr ] [ Designated as safety issue: Yes ]
  • Terminal half-life(t1/2) of Clozapine in plasma [ Time Frame: Up to 12hr ] [ Designated as safety issue: Yes ]
  • R(Accumulation Rate) of Clozapine in plasma [ Time Frame: Up tp 12hr ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg
Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients

To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.

A randomized, 2-way crossover, open, phase I study to compare the pharmacokinetics profile of DWCZP tablet 100mg and Clozaril® tablet 100mg after a multiple-dose oral administration in schizophrenia patients.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Schizophrenia
  • Drug: DWCZP
    Multiple dose
    Other Name: DWCZP Tablet 100mg
  • Drug: Clozaril
    multiple-dose
    Other Name: Clozaril Tablet 100mg
  • Experimental: A Group

    1.1st Administration - DWCZP tablet 100mg Mutiple dose

    2.2nd Administration - Clozaril tablet 100mg Mutiple dose

    Interventions:
    • Drug: DWCZP
    • Drug: Clozaril
  • Experimental: B Group

    1.1st Administration - Clozaril tablet 100mg Mutiple dose

    2.2nd Administration - DWCZP tablet 100mg Mutiple dose

    Interventions:
    • Drug: DWCZP
    • Drug: Clozaril
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
August 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult male or female within range of 20 to 60.
  • Diagnosed as Schizophrenia (Note: Diagnosed with DSM-IV, ICD-10 as a standard Schizophrenia diagnostic tool).
  • Administered clozapine for 3 months before signing agreement with same amount daily and who can administer clozapine 100mg twice (morning, evening) a day, total of 200mg during the study time.
  • One who might be pregnant must get negative result for pregnancy test (urine or blood β-hCG) before the randomization and during the study time, one must agree appropriate contraception. However, one who is using only hormone-contraceptive for birth control and has not been more that 1 year after Tubal ligation or menopause are excluded.
  • One who understood completed about this study after the explanation is given, decided to volunteer and gave written informed consent approved by IRB to participate in study in compliance with the requirement of the entire protocol.

Exclusion Criteria:

  • One who has record of hypersensitive reaction with Clozapine or other antipsychotic drug.
  • WBC count less than 4,000/ml or Absolute Neutrophil count less than 2,000/ml.
  • Administering hypertension drug or has orthostatic hypotension.
  • One who has clinical problem with kidney or liver and include following criteria: CCr < 50mL/min; BUN > 30 mg/dl; ALT 또는 AST > 3 x ULN; Total bilirubin > 2 x ULN; ALP > 2 x ULN.
  • Diagnosed to have other psychiatric or neurological problems other than Schizophrenia (e.g., Organic mental disorder, severe tardive dyskinesia, idiopathic Parkinson's disease, etc).
  • Record of Granulocytopenia or Myeloproliferative disorder in the past.
  • Record of stomach-related problems(active Crohn's disease, vital infectious intestine disease, ulcer, acute or chronic pancreatitis etc) or surgery which can affect absorption of study drug. However, simple appendectomy or herniotomy are exceptions.
  • Chronic Hepatitis B carrier, proof of Hepatitis C carrier or Hepatitis C antibody.
  • Immunodeficiency diseases such as HIV positive, AIDS, had bone marrow transplantation or has blood ammonia.
  • Record of seizure in 1 year before signing informed consent form or had administered anti-seizure drug before(e.g., Epilepsy, Convulsions, Myasthenia gravis, etc).
  • One who constantly drinks(> 21Units/week, 1Unit = 10g of pure alcohol) or cannot stop drinking alcohol during hospitalization period.
  • Smoking past 3 months before signing informed consent form or cannot stop smoking during hospitalization period.
  • One who cannot attend routine blood tests.
  • Bone marrow malfunction.
  • Mental illness, durg addicted or in coma.
  • One who has any kind of circulation imperfection and patient with depressed central nervous system.
  • Major kidney and heart problem(e.g. myocarditis).
  • Incurable epilepsy.
  • Paralytic intestinal obstruction.
  • Generic problems such as Lactose intolerance, Galactose intolerance, Lapp lactose deficiency, Glucose-Galactose absorption deficiency, etc.
  • Administered barbital-related drugs and drug metabolizing enzyme inducer and inhibitor in 1 month before starting the study.
  • One who had drugs that can affect on result of the study for past 10 days before the study start.
  • One who had whole blood donation in 2 months or blood component donation or transfusion in 1 month before signing the informed consent form.
  • Attended clinical tests or bioequivalence tests in 2 months before signing informed consent form.
  • Currently pregnant or breast-feeding or has possibility of pregnancy because one is not using medically approved contraception(Note: condoms, oral contraceptive, intrauterine device, abstinence etc).
  • One who is clinically significant by observations considered as unsuitable based on medical judgement by investigators.
Both
20 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01654601
DWCZP-I-1
No
Dong Wha Pharmaceutical Co. Ltd.
Dong Wha Pharmaceutical Co. Ltd.
  • The Catholic University of Korea
  • Konkuk University Hospital
  • Naju National Hospital
  • Seoul National Hospital
  • Wonkwang University
  • DongGuk University
Principal Investigator: Won-Myoung Bahk, M.D. The Catholic University of Korea
Dong Wha Pharmaceutical Co. Ltd.
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP